Literature DB >> 7986143

The orderly progression of melanoma nodal metastases.

D Reintgen1, C W Cruse, K Wells, C Berman, N Fenske, F Glass, K Schroer, R Heller, M Ross, G Lyman.   

Abstract

OBJECTIVE: The aim of this study was to determine the order of melanoma nodal metastases. SUMMARY BACKGROUND DATA: Most solid tumors are thought to demonstrate a random nodal metastatic pattern. The incidence of skip nodal metastases precluded the use of sampling procedures of first station nodal basins to achieve adequate pathological staging. Malignant melanoma may be different from other malignancies in that the cutaneous lymphatic flow is better defined and can be mapped accurately. The concept of an orderly progression of nodal metastases is radically different than what is thought to occur in the natural history of metastases from most other solid malignancies.
METHODS: The investigators performed preoperative and intraoperative mapping of the cutaneous lymphatics from the primary melanoma in an attempt to identify the "sentinel" lymph node in the regional basin. All patients had primary melanomas with tumor thicknesses > 0.76 mm and were considered candidates for elective lymph node dissection. The sentinel lymph node was harvested and submitted separately to pathology, followed by a complete node dissection. The null hypothesis tested was whether nodal metastases from malignant melanoma occurred in equal proportions among sentinel and nonsentinel nodes.
RESULTS: Forty-two patients met the criteria of the protocol based on prognostic factors of their primary melanoma. Thirty-four patients had histologically negative sentinel nodes, with the rest of the nodes in the basin also being negative. Thus, there were no skip metastases documented. Eight patients had positive sentinel nodes, with seven of the eight having the sentinel node as the only site of disease. In these seven patients, the frequency of sentinel nodal metastases was 92%, whereas none of the higher nodes had documented metastatic disease. Nodal involvement was compared between the sentinel and nonsentinel nodal groups, based on the binomial distribution. Under the null hypothesis of equality in distribution of nodal metastases, the probability that all seven unpaired observations would demonstrate that involvement of the sentinel node is 0.008.
CONCLUSIONS: The data presented demonstrate that nodal metastases from cutaneous melanoma are not random events. The sentinel lymph nodes in the lymphatic basins can be mapped and identified individually, and they have been shown to contain the first evidence of melanoma metastases. This information can be used to revolutionize melanoma care so that only those patients with evidence of nodal metastatic disease are subjected to the morbidity and expense of a complete node dissection. Because sentinel node histology accurately reflects the histology of the remainder of the lymphatic basin, information gained from the sentinel node biopsy can be used as a prognostic factor for melanoma. These findings demonstrate effective pathologic staging, no decrease in standards of care, and a reduction of morbidity with a less aggressive, rational surgical approach.

Entities:  

Mesh:

Year:  1994        PMID: 7986143      PMCID: PMC1234478          DOI: 10.1097/00000658-199412000-00009

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  18 in total

1.  Recurrent malignant melanoma: the identification of prognostic factors to predict survival.

Authors:  D S Reintgen; C Cox; C L Slingluff; H F Seigler
Journal:  Ann Plast Surg       Date:  1992-01       Impact factor: 1.539

2.  The concept of lymph node dissections in patients with malignant melanoma.

Authors:  C Stankard; C W Cruse; C Cox; K E Wells; J King; D S Reintgen
Journal:  Ann Plast Surg       Date:  1992-01       Impact factor: 1.539

Review 3.  Molecular basis of tumor progression: mechanisms of organ-specific tumor metastasis.

Authors:  T J Yeatman; G L Nicolson
Journal:  Semin Surg Oncol       Date:  1993 May-Jun

4.  Technical details of intraoperative lymphatic mapping for early stage melanoma.

Authors:  D L Morton; D R Wen; J H Wong; J S Economou; L A Cagle; F K Storm; L J Foshag; A J Cochran
Journal:  Arch Surg       Date:  1992-04

5.  Lymphatic drainage of skin to a sentinel lymph node in a feline model.

Authors:  J H Wong; L A Cagle; D L Morton
Journal:  Ann Surg       Date:  1991-11       Impact factor: 12.969

6.  Prophylactic lymph node dissection in clinical stage I cutaneous malignant melanoma: results of surgical treatment in 1319 patients.

Authors:  G W Milton; H M Shaw; W H McCarthy; L Pearson; C M Balch; S J Soong
Journal:  Br J Surg       Date:  1982-02       Impact factor: 6.939

7.  A comparison of prognostic factors and surgical results in 1,786 patients with localized (stage I) melanoma treated in Alabama, USA, and New South Wales, Australia.

Authors:  C M Balch; S J Soong; G W Milton; H M Shaw; V J McGovern; T M Murad; W H McCarthy; W A Maddox
Journal:  Ann Surg       Date:  1982-12       Impact factor: 12.969

8.  Distribution of axillary node metastases by level of invasion. An analysis of 539 cases.

Authors:  U Veronesi; F Rilke; A Luini; V Sacchini; V Galimberti; T Campa; E Dei Bei; M Greco; A Magni; M Merson
Journal:  Cancer       Date:  1987-02-15       Impact factor: 6.860

9.  Discontinuous or "skip" metastases in breast carcinoma. Analysis of 1228 axillary dissections.

Authors:  P P Rosen; M L Lesser; D W Kinne; E J Beattie
Journal:  Ann Surg       Date:  1983-03       Impact factor: 12.969

10.  A prospective randomized study of the efficacy of routine elective lymphadenectomy in management of malignant melanoma. Preliminary results.

Authors:  F H Sim; W F Taylor; J C Ivins; D J Pritchard; E H Soule
Journal:  Cancer       Date:  1978-03       Impact factor: 6.860

View more
  80 in total

Review 1.  Management of the clinically negative (N0) neck.

Authors:  Karen T Pitman; Robert Dean
Journal:  Curr Oncol Rep       Date:  2002-01       Impact factor: 5.075

2.  Stromal expression of vascular endothelial growth factor C is relevant to predict sentinel lymph node status in melanomas.

Authors:  Elena Gallego; Luis Vicioso; Martina Alvarez; Isabel Hierro; Lidia Pérez-Villa; Alfredo Blanes; Alfredo Matilla
Journal:  Virchows Arch       Date:  2011-01-29       Impact factor: 4.064

Review 3.  Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline.

Authors:  Sandra L Wong; Charles M Balch; Patricia Hurley; Sanjiv S Agarwala; Timothy J Akhurst; Alistair Cochran; Janice N Cormier; Mark Gorman; Theodore Y Kim; Kelly M McMasters; R Dirk Noyes; Lynn M Schuchter; Matias E Valsecchi; Donald L Weaver; Gary H Lyman
Journal:  J Clin Oncol       Date:  2012-07-09       Impact factor: 44.544

4.  The use of SPECT/CT for anatomical mapping of lymphatic drainage in vulvar cancer: possible implications for the extent of inguinal lymph node dissection.

Authors:  Angela Collarino; Maarten L Donswijk; Willemien J van Driel; Marcel P Stokkel; Renato A Valdés Olmos
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-07-30       Impact factor: 9.236

Review 5.  Clinical and biological aspects of sentinel node biopsy in malignant melanoma--an update.

Authors:  Isabel Callejo Peixoto; José Meneses e Sousa
Journal:  Clin Transl Oncol       Date:  2005-05       Impact factor: 3.405

6.  Sentinel lymph node biopsy in melanoma.

Authors:  Matthew T Hueman; Julie R Lange
Journal:  Curr Treat Options Oncol       Date:  2008-11-08

7.  EANM-EORTC general recommendations for sentinel node diagnostics in melanoma.

Authors:  Annette H Chakera; Birger Hesse; Zeynep Burak; James R Ballinger; Allan Britten; Corrado Caracò; Alistair J Cochran; Martin G Cook; Krzysztof T Drzewiecki; Richard Essner; Einat Even-Sapir; Alexander M M Eggermont; Tanja Gmeiner Stopar; Christian Ingvar; Martin C Mihm; Stanley W McCarthy; Nicola Mozzillo; Omgo E Nieweg; Richard A Scolyer; Hans Starz; John F Thompson; Giuseppe Trifirò; Giuseppe Viale; Sergi Vidal-Sicart; Roger Uren; Wendy Waddington; Arturo Chiti; Alain Spatz; Alessandro Testori
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-10       Impact factor: 9.236

Review 8.  Future perspectives: cancer metastases.

Authors:  Stanley P Leong; Jonathan S Zager
Journal:  Clin Exp Metastasis       Date:  2018-07-23       Impact factor: 5.150

9.  Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger.

Authors:  C M Balch; S J Soong; A A Bartolucci; M M Urist; C P Karakousis; T J Smith; W J Temple; M I Ross; W R Jewell; M C Mihm; R L Barnhill; H J Wanebo
Journal:  Ann Surg       Date:  1996-09       Impact factor: 12.969

10.  Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination.

Authors:  J Zachary Sanborn; Jongsuk Chung; Elizabeth Purdom; Nicholas J Wang; Hojabr Kakavand; James S Wilmott; Timothy Butler; John F Thompson; Graham J Mann; Lauren E Haydu; Robyn P M Saw; Klaus J Busam; Roger S Lo; Eric A Collisson; Joe S Hur; Paul T Spellman; James E Cleaver; Joe W Gray; Nam Huh; Rajmohan Murali; Richard A Scolyer; Boris C Bastian; Raymond J Cho
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-18       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.